Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 8OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × TAK-659 × Clear all
NCT03742258 2025-06-18

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Northwestern University

Phase 1 Completed
12 enrolled 13 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03756818 2023-02-28

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
52 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡